{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-23-000160","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.909658+00:00","generated_at":"2026-06-16T09:49:48.192738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lilly Q1 revenue $6.96B (-11%); EPS $1.49 (-29%); core biz ex-COVID +10%; guidance raised","bullets":["Revenue $6.96B, down 11% YoY; ex-COVID-19 antibodies up 10% on Mounjaro, Trulicity, Verzenio, Jardiance.","Reported EPS $1.49, down 29%; non-GAAP EPS $1.62, down 38%; both include $0.10 acquired IPR&D.","2023 reported EPS guidance raised to $8.18-$8.38; non-GAAP to $8.65-$8.85 (up $0.30).","New Products (Mounjaro, Jaypirca) contributed $573.6M; Growth Products rev $4.56B (+18%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-23-000160","json":"https://secwatch.observer/filing/0000059478-23-000160.json","markdown":"https://secwatch.observer/filing/0000059478-23-000160.md","text":"https://secwatch.observer/filing/0000059478-23-000160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/0000059478-23-000160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/lly-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T09:49:48.192738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a54cf0c9a55af27b65a87e4f5af817767d179f83","claim":"ELI LILLY & Co reported First Quarter 2023 results: revenue $6,960.0, net income $1,344.9, EPS $1.49. Guidance raised.","evidence_excerpt":"Financial Results $ in millions, except per share data First Quarter 2023 2022 % Change Revenue $6,960.0 $7,810.0 (11)% Net Income – Reported 1,344.9 1,902.9 (29)% EPS – Reported 1.49 2.10 (29)% Net Income – Non-GAAP 1,463.9 2,372.8 (38)% EPS – Non-GAAP 1.62 2.62 (38)%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/0000059478-23-000160-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$6,960.0"},{"label":"Net income","value":"$1,344.9"},{"label":"EPS","value":"$1.49"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}